KBC Securities - MDxHealth S.A. (ONCOB) mdxhealth FIRST LOOK : 3Q23 Highlights Show Sustained Improvements

Report

KBC Securities

Thomas Vranken

mdxhealth FIRST LOOK : 3Q23 Highlights Show Sustained Improvements

In anticipation of the announced Euronext delisting, mdxhealth disclosed its 3Q23 highlights ahead of the detailed results. The reported topline features a continued strong uptake in revenues to $ 19.3m (+15% q/q), while cash burn comes down markedly ahead of our expectations. We re-iterate our € 0.9 TP and Buy rating.

10/10/2023 1 EN

Underlying

MDxHealth S.A.

MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. Co. offers two main products: Clinical Molecular Diagnostics (ClinicalMDx) Solutions that provide physicians with tests for the identification and treatment of their cancer patients; and Pharmaco Molecular Diagnostics (PharmacoMDx) Solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. Co.'s ClinicalMDx solutions include ConfirmMDx, InformMDx, RecurMDx, and PredictMDx.

See profile

BE0003844611 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

GlobeNewsWire

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, d...

March 12, 2024 March 12, 2024 1 EN

GlobeNewsWire

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded by 10.7 percentage points over prior yearConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31,...

March 6, 2024 March 6, 2024 1 EN

GlobeNewsWire

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2023, after market close on Wednesday, March 6, 2...

February 21, 2024 February 21, 2024 1 EN

Qrf Model update: rental income above expectations, TP increase

QRF reports results above our estimates on higher than expected rental growth, +2,4% like-for-like, + 5,1% YoY. The negative earnings growth (- 6,96%) from the CASA bankruptcy had a € 0,09 EPRA EPS impact. Excluding this impact, EPRA EPS would have grown by 2,2%. The outlook of € 0,84 DPS remains unchanged in line with our expectations. Most impressive are the fair value gains on the recently acquired assets: + €8,4m on Feest and Cultuur Paleis and +€ 4,01 on the City 25 portfolio coming from development gains, ERV growth and even cap rate compression. With these figures QRF demonstrates its e...

55m 55m 1 EN

Wim Hoste

Wim Hoste

Recticel Feedback conference call

Below are the highlights of the conference call. FY25 adjusted EBITDA increased by 12.5% and was in line with our forecasts while being 4% above consensus. Although expecting continued volume growth in 2026, Recticel does not provide a guidance at this stage, citing ao input cost volatility. CEO Jan Vergote will become Executive Chairman, while the current CEO of Recticel's Insulation Boards division, Stefaan Debusschere, will become new group CEO. Recticel still has significant firepower for additional acquisitions and we would expect the company to continue to hunt for mid-sized acquisitions...

3h / 35m 3h / 35m 1 EN

Wim Hoste

Wim Hoste

Fugro FIRST LOOK: weak 4Q, comforting offshore wind comments, savings upped  /

FY Adj.EBIT landed at €90.9m, below our estimate (€96m) and above consensus (€84m). Resulting margin is at 4.9% (vs. our 5.2% E). Backlog for the next 12m stands at € 1396m (-5.7% comp y/y). Full year revenues were mainly derived from Oil&Gas (45%, -2% y/y) and Renewables (26%, -40% y/y). Leverage remains under control at 1.4x. As foreseen no quantitative guidance on 2026 was issued. Positive is that the savings ambition is revised to the upper end of the previous € 100-120m guidance whilst we also welcome the positive outlook comments on Offshore wind, although this is not yet reflected in th...

5h / 52m 5h / 52m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

mdxhealth FIRST LOOK : 3Q23 Highlights Show Sustained Improvements

We are a financial services provider for several types of professional clients, each with distinct needs.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

Qrf Model update: rental income above expectations, TP increase

Recticel Feedback conference call

Fugro FIRST LOOK: weak 4Q, comforting offshore wind comments, savings upped &#x07; &#x07;/

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe

Fugro FIRST LOOK: weak 4Q, comforting offshore wind comments, savings upped /